AstraZeneca has dropped Amgen-partnered bispecific T-cell engager MEDI-565 from its clinical-phase pipeline. The CEA-CD3 candidate was pitched as a treatment for colorectal cancer but looks to have come unstuck in early-phase trials.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,